glp-1/glp-2 dual agonist The Sustained Effects of a GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes: Cell Metabolism Current Insights, Advantages and Challenges
Description
About 80% of the patients were taking it for diabetes reasons, and among the total cohort, that average weight loss at 1 year was 5%
In addition to NAION, Wegovy patients may also face temporary blurred vision from fluctuating blood sugar levels, an increase in eye infections, and other vision issues
In the last 10 to 15 years, discoveries on certain gut peptides that influence insulin secretion related to meal ingestion, namely incretins, have opened up a new paradigm in the treatment of diabetes [4]
What began as an unexpected observation and side effect of some medications converged with decades of addiction neuroscience: GLP-1 receptor agonist medications like Ozempic apparently reduce alcohol craving, drinking intensity, and relapses
[DOI] [PubMed] [Google Scholar] 98.Jin T., Drucker D.J
Despite these promising findings, the underlying mechanisms, particularly those involving incretin hormones, require further elucidation
